If you searched for "Garzulys vs. NovoLog," there's a decent chance your pharmacist mentioned the name Garzulys for the first time this month, or you saw a headline about a new NovoLog biosimilar and wondered whether it's worth asking about. Fair question — insulin pricing has genuinely improved over the past couple of years, and a new lower-cost option landing in that mix sounds like good news. It might be. But because Garzulys only received FDA approval a couple of weeks before this article was written, a lot of the specifics people usually want — exact price, whether their plan covers it, whether a savings card exists — simply aren't public yet. We'd rather tell you that clearly than fill in numbers that don't exist.
1. What Is Garzulys?
Garzulys, generic name insulin aspart-fsan, is a rapid-acting insulin analog that the FDA approved on July 30, 2026 to improve glycemic control in adults and children with diabetes. Functionally, it behaves the way any mealtime insulin aspart product does: injected roughly 5 to 10 minutes before eating, it starts working quickly to blunt the blood sugar rise from a meal, and it's typically paired with a longer-acting basal insulin as part of a full regimen rather than used on its own.
It comes in the two formats you'd expect from a modern insulin: a 3 mL single-patient-use prefilled pen and a 10 mL multiple-dose vial, both at the standard U-100 concentration. The vial is approved for subcutaneous injection, continuous subcutaneous infusion through a compatible insulin pump, and intravenous administration in clinical settings — the last of those is something a hospital or clinic would do, not something you'd do at home.
The corporate story behind Garzulys is a little more layered than most branded insulins, which is worth knowing because it explains why the name "Meitheal" shows up in the press coverage but isn't the only company involved:
- Tonghua Dongbao Pharmaceutical (China) developed the drug substance.
- Nanjing King-Friend Biochemical Pharmaceutical handled drug product development.
- Xentria, Inc. led the clinical development program that supported the FDA application.
- Emerge Bioscience holds the actual FDA-approved Biologics License Application (BLA) — the legal marketing authorization.
- Meitheal Pharmaceuticals, a Chicago-based company better known for generic injectables, is the U.S. regulatory agent and holds exclusive commercial rights to sell it here.
None of that changes how the drug works in your body, but it does explain why "who makes Garzulys" doesn't have a single one-word answer, and why some of the infrastructure that established brands have — patient savings hotlines, long-running assistance programs, deep pharmacy relationships — hasn't necessarily caught up yet for a product this new.
2. Is Garzulys the Same as NovoLog?
Close, but not literally the same product, and that distinction matters more than it might sound like it should. Garzulys is a biosimilar to NovoLog, meaning the FDA reviewed a substantial data package — analytical comparisons, clinical studies — and concluded there are no clinically meaningful differences between Garzulys and NovoLog in safety, purity, or potency. The two are close enough that switching between them isn't expected to change how well your blood sugar is controlled.
What's not the same is the regulatory box each one checks. NovoLog is the original, FDA-approved "reference product." Garzulys is biosimilar to it but does not currently hold an interchangeable designation — a separate, higher bar that one of the other two NovoLog biosimilars, Kirsty, has already cleared. We'll unpack exactly what that distinction means for your prescription in the interchangeability section below, because it's the single most practical difference between these two products.
3. Garzulys vs. NovoLog: Comparison Table
| Detail | Garzulys | NovoLog |
|---|---|---|
| Manufacturer / marketer | Meitheal Pharmaceuticals (BLA holder: Emerge Bioscience) | Novo Nordisk |
| FDA status | Biosimilar | Reference (original) product |
| Interchangeable designation | No | Not applicable — it's the reference product |
| FDA approval date | July 30, 2026 | Originally approved 2000 |
| Formulations | 10 mL multi-dose vial; 3 mL prefilled pen | 10 mL vial; FlexPen; FlexTouch; PenFill cartridges |
| Strength | U-100 (100 units/mL) | U-100 (100 units/mL) |
| Administration | SC injection, insulin pump (CSII), IV (clinical use) | SC injection, insulin pump (CSII), IV (clinical use) |
| Onset / mealtime use | 5–10 minutes before eating | 5–10 minutes before eating |
| Public list price (WAC) | Not yet published | Cut substantially effective Jan. 1, 2026 |
| GoodRx / discount-card listing | Not yet listed as of Aug. 2026 | Listed — vial from roughly $79–$82 with coupon |
| Manufacturer savings card | None announced yet | My Insulin Rx, caps at $35/month for eligible patients |
| Medicare Part D formulary presence | Not yet confirmed on all plans | Widely covered |
Read the "pending" rows literally. They don't mean "bad" or "expensive" — they mean the information hadn't been made public as of when we researched this guide. A brand-new biosimilar typically takes a few weeks to months to show up in pricing databases, savings-card programs, and insurance formularies after FDA approval. We'll update this table as real numbers appear.
4. Where Garzulys Fits in the Insulin Aspart Lineup
Garzulys didn't arrive into an empty field. It's the third FDA-approved biosimilar referencing NovoLog, and knowing where it sits relative to the other two tells you something useful: this category is maturing, but slowly, and the products aren't interchangeable with each other any more than they're interchangeable with NovoLog itself.
| Product | Manufacturer | Approved | Interchangeable? |
|---|---|---|---|
| NovoLog (insulin aspart) | Novo Nordisk | Reference product | N/A |
| Merilog (insulin aspart-szjj) | Sanofi | February 2025 | No |
| Kirsty (insulin aspart-xjhz) | Biocon Biologics | July 15, 2025 | Yes — first interchangeable insulin aspart |
| Garzulys (insulin aspart-fsan) | Meitheal Pharmaceuticals | July 30, 2026 | No |
One nuance most quick summaries skip: interchangeable status has nothing to do with which biosimilar came first or which one is "better." Kirsty earned its interchangeable label through a specific type of switching study the FDA requires for that designation — proving that alternating back and forth between Kirsty and NovoLog doesn't reduce safety or effectiveness compared with staying on NovoLog alone. Merilog and Garzulys simply haven't pursued or received that same designation, at least not yet. A biosimilar can seek interchangeable status later, even after its initial approval, so this picture isn't necessarily permanent.
5. Cost Comparison
Let's start with what NovoLog costs today, because that side of the comparison is well documented. Novo Nordisk cut list prices on its insulin portfolio effective January 1, 2026, and it shows: a NovoLog vial now runs around $79 to $82 with a GoodRx coupon against an average retail price near $126, and a box of five FlexPens tends to run higher, commonly in the $290 to $350 range depending on the pharmacy and whether a coupon applies. Without any discount at all, cash-pay prices for insulin aspart products can still run considerably higher — into the hundreds of dollars for a full package — which is exactly why coupons and insurance matter so much here.
Now the honest gap: Garzulys's price hasn't been published. As of mid-August 2026, we couldn't find a wholesale acquisition cost (WAC), a GoodRx listing, or a manufacturer-quoted cash price for Garzulys anywhere in pharmaceutical pricing databases or trade coverage. That's not unusual — new biosimilars often launch weeks after approval, and public pricing data tends to lag the actual launch by some amount of time as it works through wholesalers and pricing services.
Don't assume "biosimilar" automatically means "dramatically cheaper." A 2026 cost-modeling analysis presented at ISPOR compared the two earlier NovoLog biosimilars, Kirsty and Merilog, against NovoLog itself and found real but modest savings — roughly $10 to $91 per patient per year depending on daily insulin dose, not the steep discounts biosimilars sometimes produce in other drug categories. Interestingly, the same analysis noted Kirsty and Merilog carry essentially identical wholesale prices to each other. Insulin biosimilar pricing so far has tracked closer to "modest, steady savings" than "dramatic price collapse" — worth keeping in mind before assuming Garzulys will undercut NovoLog by a wide margin.
There's also a second factor working against a huge gap: NovoLog's own list price already dropped sharply this year. A biosimilar's main selling point is usually "cheaper than the brand," and when the brand itself gets cheaper first, the room for a biosimilar to undercut it by a lot simply shrinks. That doesn't mean Garzulys won't end up cheaper — it very well might, especially once insurance contracts and rebates are factored in rather than list price alone — but "might save you something modest" is a more realistic expectation than "will definitely cost far less."
6. Insurance Coverage
Insurance coverage for any drug comes down to whether it's on your plan's formulary — the specific list of drugs a plan agrees to pay toward — and if so, which cost-sharing tier it lands on. NovoLog has been on the market for over two decades and is a formulary staple for the vast majority of Medicare and commercial plans. Garzulys, by contrast, is a few weeks old. Formularies aren't updated the instant a drug is approved; plans typically review new products on their own internal timelines, sometimes tied to quarterly or annual formulary cycles.
Practically, this means the honest answer to "does my insurance cover Garzulys" right now is: check directly, don't assume either way. Some plans move quickly to add new lower-cost biosimilars because it can reduce their own drug spend. Others take months. There's no universal timeline you can rely on.
7. Medicare Coverage
Medicare Part D's insulin rules are genuinely good news for anyone on a covered insulin product — but the word "covered" is doing real work in that sentence. Under the Inflation Reduction Act, your out-of-pocket cost for any insulin product that's on your Part D plan's formulary is capped at $35 per month's supply, with no deductible applied first, across every phase of the Part D benefit. If you qualify for the Extra Help / Low-Income Subsidy program, you'll typically pay even less — generally $0 to $12.65 per covered insulin prescription in 2026. The Part D annual out-of-pocket cap for 2026 is $2,100, and those $35 insulin payments count toward reaching it.
The catch, spelled out plainly: the $35 cap applies per insulin product that your specific plan covers — it doesn't retroactively apply to a drug just because it's FDA-approved. NovoLog is well established on Part D formularies, so the cap almost certainly applies if you're already filling it through Medicare. Garzulys is new enough that it may not yet appear on every 2026 Part D plan's formulary. If your prescriber suggests switching you to Garzulys, confirm with your specific plan — not just "Medicare" in general — that it's covered before you fill it, so you're not caught paying full price while the paperwork catches up.
If you want the fuller picture on Extra Help eligibility and how it interacts with insulin costs, our Medicare Extra Help (LIS) guide walks through qualification and enrollment.
8. Commercial Insurance
Outside of Medicare, there's no federal $35 cap. Commercial plans — employer coverage, ACA marketplace plans — set their own insulin cost-sharing, though more than 30 states have passed their own insulin copay caps for state-regulated plans, commonly around $25 to $35 per month, with a few set higher. One important wrinkle: large, self-funded employer plans governed by ERISA are often exempt from state insurance laws, so a state cap doesn't automatically apply just because you live in a state that has one — it depends on how your specific plan is structured.
For NovoLog, most commercial plans that cover insulin at all include it on formulary, often as a preferred product given its long market history. For Garzulys, the same uncertainty from the Medicare section applies: pharmacy benefit managers (PBMs) add new biosimilars to formularies on their own schedules, and a PBM's decision to prefer or exclude a specific biosimilar is often driven by rebate contracts with manufacturers — a business detail that has nothing to do with clinical quality and everything to do with net cost to the plan.
9. Cash-Pay & Out-of-Pocket Considerations
If you're uninsured, your deductible hasn't kicked in yet, or your plan simply doesn't cover the product you're on, cash pricing is what you're actually paying at the counter. For NovoLog, that picture is well established: discount cards like GoodRx currently show vial pricing around $79 to $82, with pen packages running higher. Costco and Walmart pharmacies are also worth checking, since both frequently post competitive cash prices on insulin.
For Garzulys, cash pricing simply isn't published yet in the tools most people use to compare prices. That means your most reliable move right now, if you're specifically curious about Garzulys cash cost, is to call a pharmacy directly and ask whether they can order it and what it would cost — rather than relying on an app that hasn't caught up to a two-week-old drug.
10. Savings Programs
NovoLog has a mature savings infrastructure behind it. Novo Nordisk's My Insulin Rx program lets eligible uninsured or underinsured patients pay $35 for a monthly supply of up to three vials or two packs of pens — a program that cannot be combined with Medicare but can be a strong option if you don't have Part D coverage. Sanofi, for comparison, capped Merilog at $35 or less for a 30-day supply when it launched in 2025, showing that manufacturer-backed price caps have become fairly standard for new insulin products in this category.
No Garzulys-specific savings card had been publicly announced as of mid-August 2026. Given that Sanofi announced a savings cap for Merilog around its own launch, there's a reasonable chance Meitheal or Emerge will roll out something comparable for Garzulys — but as of this writing, nothing had been formally published. If cost is a driving factor in your decision, ask your pharmacist or check Meitheal's official patient materials directly for the latest before assuming a program exists.
If a savings card genuinely isn't available for whatever insulin you're on, our guide to free and $35 insulin options in the US and our breakdown of how patient assistance programs work cover the broader landscape of options beyond a single manufacturer's card.
11. Biosimilar vs. Reference Product, Explained
"Biosimilar" gets thrown around casually, so it's worth being precise about what the FDA actually requires. Insulin is a biologic — grown using living cells rather than synthesized chemically — which is why it doesn't have a traditional AB-rated generic the way a pill like metformin does. Instead, the FDA created a biosimilar approval pathway specifically for biologics.
To earn biosimilar approval, a manufacturer has to show the FDA that its product is highly similar to an already-approved reference product — in this case, NovoLog — with no clinically meaningful differences in safety, purity, or potency. Minor differences in inactive ingredients are allowed, since those don't affect how the drug performs in the body. This is a rigorous, evidence-based pathway; it is not a shortcut around clinical scrutiny, even though it moves faster than an entirely new drug application because it leverages the reference product's existing safety record.
What a plain biosimilar approval does not automatically grant is the ability for a pharmacist to substitute it for the reference product the way they would with a small-molecule generic. That additional permission is a separate designation — interchangeability — which is the subject of the next section.
12. Interchangeability — Don't Assume It
This is the part of the Garzulys story most worth slowing down for, because it's easy to assume "biosimilar" and "interchangeable" mean the same thing. They don't, and the difference has a direct, practical effect on how your prescription gets filled.
In practice, this means if you or your doctor decide Garzulys is worth trying, the prescription needs to name Garzulys specifically — not just "insulin aspart" — and your pharmacy needs a valid script for that exact product before they can dispense it in place of NovoLog.
13. Which One May Cost Less?
Given everything above, here's the fairest way to frame this rather than pretending we can give you a definitive number: your actual cost for either drug is going to be driven far more by your specific insurance formulary and tier placement than by which product is inherently cheaper on paper. A few realistic scenarios:
- If you have Medicare Part D and NovoLog is on your formulary, you're already capped at $35/month for NovoLog — a hard number that's difficult for an unlisted new biosimilar to beat, at least until Garzulys is confirmed on your specific formulary.
- If you're uninsured or cash-pay, NovoLog's current GoodRx pricing (roughly $79 to $82 per vial) is a known number you can act on today. Garzulys's cash price is still an unknown, so there's nothing concrete to compare it against yet.
- If your commercial plan doesn't currently cover NovoLog well — high tier, high coinsurance — it's worth asking whether Garzulys, once available through your pharmacy, might land on a more favorable tier. PBMs sometimes place biosimilars on preferred tiers specifically to steer volume toward them.
The short version: don't switch based on an assumption that "biosimilar equals cheaper." Get an actual quote — from your pharmacy, from your insurer, or both — before making a change.
14. What Happens If Insurance Prefers One Over the Other?
Insurers occasionally change which product they prefer on a formulary — moving a drug to a non-preferred tier, adding a new biosimilar as the preferred option, or dropping coverage for a product they previously covered. When this happens for reasons unrelated to your individual medical need, it's often called non-medical switching, and it can be frustrating if you've been stable on a particular insulin for years.
Because Garzulys isn't interchangeable, any change from NovoLog to Garzulys requires your prescriber to write a new or updated prescription regardless of what your insurer prefers.
15. What to Ask Your Pharmacist
"Do you currently stock Garzulys, or would you need to order it?" New products don't always sit on every pharmacy's shelf immediately after launch.
"What would my cash price be for Garzulys, if I don't use insurance?" Since it isn't on discount-card apps yet, the pharmacy's own quote is currently the most reliable number available.
"Is my current prescription written specifically for NovoLog, or generically for insulin aspart?" This determines whether Garzulys can be filled against it at all.
"Has my insurance flagged any change to my insulin coverage recently?" Pharmacists often see formulary changes show up as claim rejections before you get a formal notice.
16. What to Ask Your Insurance Company
"Is insulin aspart-fsan (Garzulys) on my plan's current formulary, and at what tier?" Use the drug's generic name, not just the brand, since formulary listings sometimes lag brand-name updates.
"If Garzulys isn't covered, is there a formulary exception process I can use if my doctor prescribes it?"
"Has NovoLog's tier or cost-sharing changed for this plan year?" Worth confirming even if you're not planning to switch anything.
"If I have Medicare Part D, does the $35 insulin cap currently apply to Garzulys under my specific plan?" Remember, the cap only applies to products your plan actually covers.
17. Real-World Cost Scenarios
These are hypothetical examples meant to illustrate how the moving pieces above interact — not predictions of what you personally will pay.
Hypothetical: Medicare Part D, NovoLog
A Medicare beneficiary already filling NovoLog through a Part D plan that covers it pays $35 for a month's supply, regardless of list price, thanks to the IRA cap. Switching to Garzulys would only make sense once it's confirmed on that same plan's formulary — otherwise there's a real risk of paying full price during a gap in coverage.
Confirm formulary status firstHypothetical: Uninsured, cash-pay
Someone paying cash today has a known NovoLog vial price around $79–$82 with a coupon. Since Garzulys cash pricing isn't published, this person's most useful move is calling a pharmacy that stocks it directly, rather than assuming a discount app will show a lower number.
Call the pharmacy directlyHypothetical: Employer plan, formulary change notice
An employee gets a letter saying NovoLog is moving to a non-preferred tier next quarter. Before switching anything, they'd confirm with HR/benefits whether a specific aspart biosimilar — Garzulys, Merilog, or Kirsty — is the new preferred product, and ask their doctor to write for that exact one.
Get the new prescription in writingReasons Garzulys Is Worth Watching
- One more competitor in the insulin aspart market, which historically nudges net prices down over time
- Same clinical profile as NovoLog, per FDA biosimilar review standards
- Available in both vial and prefilled pen, matching NovoLog's most common formats
- Backed by an established generic-injectables manufacturer with U.S. commercial infrastructure
Reasons to Wait and See
- No public list price, cash price, or savings card as of mid-August 2026
- Not interchangeable — requires a new, specific prescription rather than a pharmacy-level swap
- Insurance formulary coverage is unconfirmed and will vary by plan
- NovoLog's own 2026 price cuts already narrowed the savings a biosimilar needs to deliver
If cost is your main concern right now
Rather than waiting on Garzulys specifics, it's worth checking whether you already qualify for something with known, confirmed pricing today: Novo Nordisk's My Insulin Rx program for NovoLog, the Medicare $35 cap if you have Part D, or a state insulin copay cap if your commercial plan is state-regulated. Our GoodRx vs. insurance comparison can also help you figure out which route is cheaper for your specific NovoLog fill while Garzulys pricing settles.